Log in or Sign up
to access My Account functionalities
DHPC Letter for Healthcare professional - Topiramate: Introduction of new contraindications and Pregnancy Prevention Programme
Janssen Cilag Ltd, in agreement with the other UK marketing authorisation holders of topiramate and the Medicines and Healthcare products Regulatory Agency (MHRA), are contacting you to inform you of the implementation of a Pregnancy Prevention Programme (PPP) for the use of topiramate-containing medicinal products in patients of childbearing potential. This PPP is being implemented following a review of safety data relating to the use of topiramate in pregnancy.